Shreyas Gaikwad

Dr. Shreyas Gaikwad

Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Abilene, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
Shreyas GaikwadShreyas Gaikwad
Shreyas Gaikwad
Sanjay K. SrivastavaSanjay K. Srivastava
Sanjay K. Srivastava
Over the past few decades, research on reactive oxygen species (ROS) has revealed their critical role in the initiation and progression of cancer by virtue of various transcription factors. At certain threshold values, ROS act as signaling molecules leading to activation of oncogenic pathways. However, if perturbated beyond the threshold values, ROS act in an anti-tumor manner leading to cellular death. ROS mediate cellular death through various programmed cell death (PCD) approaches such as apoptosis, autophagy, ferroptosis, etc. Thus, external stimulation of ROS beyond a threshold is considered a promising therapeutic strategy. Phytochemicals have been widely regarded as favorable therapeutic options in many diseased conditions. Over the past few decades, mechanistic studies on phytochemicals have revealed their effect on ROS homeostasis in cancer. Considering their favorable side effect profile, phytochemicals remain attractive treatment options in cancer. Herein, we review some of the most recent studies performed using phytochemicals and, we further delve into the mechanism of action enacted by individual phytochemicals for PCD in cancer.

Verified
Journal Article
Open access
PDF file
NGNehal Gupta
Nehal Gupta
Shreyas GaikwadShreyas Gaikwad
Shreyas Gaikwad
IKItishree Kaushik
Itishree Kaushik
SWStephen E. Wright
Stephen E. Wright
Maciej MarkiewskiMaciej Markiewski
Maciej Markiewski
Sanjay K. SrivastavaSanjay K. Srivastava
Sanjay K. Srivastava
A major contributing factor in triple-negative breast cancer progression is its ability to evade immune surveillance. One mechanism for this immunosuppression is through ribosomal protein S19 (RPS19), which facilitates myeloid-derived suppressor cells (MDSCs) recruitment in tumors, which generate cytokines TGF-β and IL-10 and induce regulatory T cells (Tregs), all of which are immunosuppressive and enhance tumor progression. Hence, enhancing the immune system in breast tumors could be a strategy for anticancer therapeutics. The present study evaluated the immune response of atovaquone, an antiprotozoal drug, in three independent breast-tumor models. Our results demonstrated that oral administration of atovaquone reduced HCC1806, CI66 and 4T1 paclitaxel-resistant (4T1-PR) breast-tumor growth by 45%, 70% and 42%, respectively. MDSCs, TGF-β, IL-10 and Tregs of blood and tumors were analyzed from all of these in vivo models. Our results demonstrated that atovaquone treatment in mice bearing HCC1806 tumors reduced MDSCs from tumor and blood by 70% and 30%, respectively. We also observed a 25% reduction in tumor MDSCs in atovaquone-treated mice bearing CI66 and 4T1-PR tumors. In addition, a decrease in TGF-β and IL-10 in tumor lysates was observed in atovaquone-treated mice with a reduction in tumor Tregs. Moreover, a significant reduction in the expression of RPS19 was found in tumors treated with atovaquone.

1 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
BPBhaumik Chandubhai Patel
Bhaumik Chandubhai Patel
ASASHOK Silwal
ASHOK Silwal
MEMohamed Ashraf Eltokhy
Mohamed Ashraf Eltokhy
Shreyas GaikwadShreyas Gaikwad
Shreyas Gaikwad
MCMarina Curcic
Marina Curcic
Sahdeo PrasadSahdeo Prasad
Sahdeo Prasad
Background: CD59, a GPI-anchored membrane protein, protects cancer cells from complement-dependent cytotoxicity (CDC) by inhibiting the formation of the membrane attack complex (MAC). It has been demonstrated to be overexpressed in most solid tumors, where it facilitates tumor cell escape from complement surveillance. The role of CD59 in cancer growth and interactions between CD59 and immune cells that modulate immune evasion has not been well explored. Methods: Using cancer patient database from The Cancer Genome Atlas (TCGA) and other public databases, we analyzed CD59 expression, its prognostic significance, and its association with immune cell infiltration in the tumor microenvironment, identifying associated genomic and functional networks and validating findings with invitro cell-line experimental data. Results: This article describes the abundant expression of CD59 in multiple tumors such as cervical squamous cell carcinoma (CESC), kidney renal cell carcinoma (KIRC), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), and stomach adenocarcinoma (STAD), as well as in pan-cancer, using The Cancer Genome Atlas (TCGA) database and confirmed using multiple cancer cell lines. The expression of CD59 significantly alters the overall survival (OS) of patients with multiple malignancies such as CESC, GBM, HNSC, and STAD. Further, the correlation between CD59 and Treg and/or MDSC in the tumor microenvironment (TME) has shown to be strongly associated with poor outcomes in CESC, GBM, HNSC, and STAD as these tumors express high FOXP3 compared to KIRC. Moreover, unfavorable outcomes were strongly associated with the expression of CD59 and M2 tumor-associated macrophage infiltration in the TME via the IL10/pSTAT3 pathway in CESC and GBM but not in KIRC. In addition, TGFβ1-dominant cancers such as CESC, GBM, and HNSC showed a high correlation between CD59 and TGFβ1, leading to suppression of cytotoxic T cell activity. Conclusion: Overall, the correlation between CD59 and immune cells predicts its prognosis as unfavorable in CESC, GBM, HNSC, and STAD while being favorable in KIRC.

8 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MAManas Yogendra Agrawal
Manas Yogendra Agrawal
Shreyas GaikwadShreyas Gaikwad
Shreyas Gaikwad
SSSangeeta Srivastava
Sangeeta Srivastava
Sanjay K. SrivastavaSanjay K. Srivastava
Sanjay K. Srivastava
In an attempt to find a potential cure for cancer, scientists have been probing the efficacy of the food we eat and its bioactive components. Over the decades, there has been an exponentially increasing trend of research correlating food and cancer. This review explains the molecular mechanisms by which bioactive food components exhibit anticancer effects in several cancer models. These bioactive compounds are mainly plant based or microbiome based. While plants remain the primary source of these phytochemicals, little is known about probiotics, i.e., microbiome sources, and their relationships with cancer. Thus, the molecular mechanisms underlying the anticancer effect of probiotics are discussed in this review. The principal mode of cell death for most food bioactives is found to be apoptosis. Principal oncogenic signaling axes such as Akt/PI3K, JAK/STAT, and NF-κB seem to be modulated due to these bioactives along with certain novel targets that provide a platform for further oncogenic research. It has been observed that probiotics have an immunomodulatory effect leading to their chemopreventive actions. Various foods exhibit better efficacy as complete extracts than their individual phytochemicals, indicating an orchestrated effect of the food components. Combining bioactive agents with available chemotherapies helps synergize the anticancer action of both to overcome drug resistance. Novel techniques to deliver bioactive agents enhance their therapeutic response. Such combinations and novel approaches are also discussed in this review. Notably, most of the food components that have been studied for cancer have shown their efficacy in vivo. This bolsters the claims of these studies and, thus, provides us with hope of discovering anticancer agents in the food that we eat.

15 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HNHONG-MY NGUYEN
HONG-MY NGUYEN
Shreyas GaikwadShreyas Gaikwad
Shreyas Gaikwad
MOMariam sciences Oladejo
Mariam sciences Oladejo
WPWyatt Paulishak
Wyatt Paulishak
LWLaurence Michael Wood
Laurence Michael Wood
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in both men and women in the United States. While immune checkpoint inhibitor (ICI) therapy is demonstrating remarkable clinical responses, the resistance and immune-related toxicities associated with ICIs demonstrate the need to develop additional immunotherapy options for CRC patients. Cancer vaccines represent a safe and promising treatment approach for CRC. As previously developed tumor-associated antigen (TAA)-based cancer vaccines for CRC are not demonstrating promising results, we propose that interferon-stimulated gene 15 (ISG15) is a novel TAA and therapeutic target for CRC. Our work demonstrates the anti-tumor efficacy of a Listeria-based vaccine targeting ISG15, designated Lm-LLO-ISG15, in an immunocompetent CRC murine model. The Lm-LLO-ISG15-mediated anti-tumor response is associated with an increased influx of functional T cells, higher production of multiple intracellular cytokines response, a lower number of regulatory T cells, and a greater ratio of effector to regulatory T cells (Teff/Treg) in the tumor microenvironment.

15 April 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
IKItishree Kaushik
Itishree Kaushik
RRRobin Rajan
Robin Rajan
Shreyas GaikwadShreyas Gaikwad
Shreyas Gaikwad
MEMohamed Ashraf Eltokhy
Mohamed Ashraf Eltokhy
Sanjay K. SrivastavaSanjay K. Srivastava
Sanjay K. Srivastava
Glioblastoma multiforme (GBM) is a lethal and aggressive cancer with an extremely poor prognosis. Recent preclinical, clinical, and genomic studies have highlighted the role of the Hippo–Yap pathway in the progression of GBM. In addition, it has been identified that YAP plays a major role in creating an immunosuppressive tumor microenvironment, facilitating drug resistance, recurrence, and metastasis of GBM tumors. In this study, we report that “moxidectin”, an antihelminthic drug, inhibits the proliferation of SF268, SF295, SF188, and CT-2A-Luc GBM cells by inducing apoptosis. Immunoblotting and immunofluorescence data show that moxidectin mediates its effects by inhibiting the MEK–ERK pathway, a regulator of Hippo–YAP signaling. Inhibition of MEK–ERK by moxidectin ultimately led to blockade of the nuclear translocation and transcriptional activity of the YAP/TAZ-TEAD complex in various GBM cells. Oral administration of 3.5 mg/kg moxidectin suppressed the growth of GBM tumors by 90% in an intracranial tumor model. Ex vivo analysis of excised tumors confirmed the observations made in in vitro studies. Interestingly, moxidectin enhanced antigen presentation in the tumor-draining lymph nodes and reduced the pro-tumorigenic macrophage population in the brain, indicating that it might play a role in modulating the immune response. Chronic moxidectin treatment did not cause any toxicity in mice based on our toxicologic evaluation. Moxidectin is an FDA-approved drug, and findings from our study will promote its clinical investigation as a potential therapeutic agent for patients with GBM.